Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 40 clinical trials
Acute Promyelocytic Leukemia 2006 (APL)

To assess the role of Arsenic trioxide and/or ATRA during consolidation course in APL. It is hoped that the investigational arms will further increase the event-free survival at 2 years, with reduced toxicity and without increasing the relapse rate by comparison with a classical anthracycline-AraC consolidation regimen.

tretinoin
anthracyclines
idarubicin
arsenic
  • 13 views
  • 07 Nov, 2020
  • 1 location
Thalidomide Cyclophosphamide Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma

researchers have chosen a regimen which can be administered on an outpatient basis. Induction therapy: To evaluate the efficacy and toxicity of thalidomide, cyclophosphamide, oral idarubicin and

cyclophosphamide
refractory multiple myeloma
thalidomide
progressive disease
plasma cell leukemia
  • 8 views
  • 07 Nov, 2020
  • 1 location
Cladribine Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)

The purpose of this study is to evaluate the safety and the efficacy of cladribine, high-dose cytarabine and idarubicin in the treatment of patients with relapsed acute myeloid leukemia.

remission
idarubicin
cytarabine
cladribine
  • 14 views
  • 07 Nov, 2020
  • 1 location
Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients

This study evaluates Idarubicin (IDA) in combination with the intermediate-dose cytarabine, compared with intermediate-dose cytarabine alone, as a consolidation treatment for elderly AML in

  • 0 views
  • 23 Jan, 2021
  • 1 location
FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML

- To determine the feasibility of fludarabine and cytarabine as continuous infusion plus idarubicin with granulocyte-colony stimulating factor priming for patients with resistant acute

colony stimulating factor
fludarabine
granulocyte colony stimulating factor
idarubicin
acute promyelocytic leukemia
  • 22 views
  • 07 Nov, 2020
  • 1 location
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia

with ATRA and idarubicin followed by postremission therapy with daunorubicin and mitoxantrone in age adapted dosages. Patients with an high WBC were additionally treated with cytarabine

methotrexate
idarubicin
mitoxantrone
retinoids
consolidation therapy
  • 40 views
  • 07 Nov, 2020
  • 1 location
Efficacy of G-CSF-Priming in Elderly AML Patients

Aim of the study is to compare the efficacy of intensive induction therapy with Cytarabine, Idarubicin and Etoposide (IdAV) given in parallel with (G-CSF priming) and followed by G-CSF

fludarabine
neoadjuvant therapy
granulocyte colony stimulating factor
idarubicin
secondary acute myeloid leukemia
  • 50 views
  • 07 Nov, 2020
  • 1 location
Treatment Protocol for Non-Metastatic Unilateral Retinoblastoma

This protocol provides guidelines for the management of non-metastatic unilateral retinoblastoma and introduces an innovative adjuvant therapy for higher risk patients based upon the results of the Grupo de America Latina de Oncologia Pediatrica (GALOP) I study. Conservative therapy will be not protocolized.

  • 48 views
  • 23 Jan, 2021
  • 1 location
Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)

The purpose of this study is to compare the clinical efficacy and safety of IAC regimen and IA regimen as induction chemotherapy for initial diagnosed AML patients. 840 cases are supposed to recruited in 3 years.

ara-c
cladribine
idarubicin
induction chemotherapy
cytarabine
  • 26 views
  • 24 Jan, 2021
  • 1 location
Study to Improve OS in 18 to 60 Year-old Patients Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60 year-old) patients, with AML risk-adapted patient strategies. Within the intermediate risk AML group, optimal GvHD prophylaxis following …

vosaroxin
consolidation chemotherapies
methotrexate
granulocyte colony stimulating factor
blast cells
  • 42 views
  • 25 Jan, 2021
  • 57 locations